Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 583461, 8 pages
http://dx.doi.org/10.1155/2014/583461
Research Article

Stability of Ceftiofur Sodium and Cefquinome Sulphate in Intravenous Solutions

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780 Poznań, Poland

Received 3 March 2014; Accepted 19 May 2014; Published 3 June 2014

Academic Editor: Sadhana J. Rajput

Copyright © 2014 Agnieszka Dołhań et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Zaffiri, J. Gardner, and L. H. Toledo-Pereyra, “History of antibiotics: from salvarsan to cephalosporins,” Journal of Investigative Surgery, vol. 25, no. 2, pp. 67–77, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Zalewski and J. Cielecka-Piontek, “Cefoselina—nowa cefalosporyna czwartej generacji,” Annales Academiae Medicae Silesiensis, vol. 65, pp. 77–81, 2011. View at Google Scholar
  3. Food and Drug Administration, “Animal drugs, feeds and relative products—ceftiofur sterile powder,” Federal Register, vol. 53, pp. 5369–5370, 1988. View at Google Scholar
  4. Food and Drug Administration, “Implantation injectable dosage form, animal drugs not subject to certification—ceftiofur sterile powder,” Federal Register, vol. 56, pp. 112–119, 1991. View at Google Scholar
  5. Food and Drug Administration, “Implantation injectable dosage form, new animal drugs—ceftiofur sterile powder for injection,” Federal Register, vol. 57, p. 41862, 1992. View at Google Scholar
  6. R. E. Hornish and S. F. Kotarski, “Cephalosporins in veterinary medicine—ceftiofur use in food animals,” Current Topics in Medicinal Chemistry, vol. 2, no. 7, pp. 717–731, 2002. View at Google Scholar · View at Scopus
  7. S. A. Salmon, J. L. Watts, C. A. Case, L. J. Hoffman, H. C. Wegener, and R. J. Yancey Jr., “Comparison of MICs of ceftiofur and other antimicrobial agents against bacterial pathogens of swine from the United States, Canada, and Denmark,” Journal of Clinical Microbiology, vol. 33, no. 9, pp. 2435–2444, 1995. View at Google Scholar · View at Scopus
  8. R. J. Erskine, R. C. Wilson, J. W. Tyler, K. A. McClure, R. S. Nelson, and H. J. Spears, “Ceftiofur distribution in serum and milk from clinically normal cows and cows with experimental Escherichia coli-induced mastitis,” American Journal of Veterinary Research, vol. 56, no. 4, pp. 481–485, 1995. View at Google Scholar · View at Scopus
  9. C. Stanek and J. Kofler, “On the treatment of complicated septic disorders of the bovine digit, using a combination of surgical therapy and application of Sodium-Ceftiofur,” Tierarztliche Praxis Ausgabe G: Grosstiere/Nutztiere, vol. 26, no. 6, pp. 314–317, 1998. View at Google Scholar · View at Scopus
  10. H. J. Wisselink, K. T. Veldman, C. Van Den Eede, S. A. Salmon, and D. J. Mevius, “Quantitative susceptibility of Streptococcus suis strains isolated from diseased pigs in seven European countries to antimicrobial agents licenced in veterinary medicine,” Veterinary Microbiology, vol. 113, no. 1-2, pp. 73–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. P. S. Jaglan, M. F. Kubicek, T. S. Arnold et al., “Metabolism of ceftiofur. Nature of urinary and plasma metabolites in rats and cattle,” Journal of Agricultural and Food Chemistry, vol. 37, no. 4, pp. 1112–1118, 1989. View at Google Scholar · View at Scopus
  12. P. S. Jaglan, B. L. Cox, T. S. Arnold, M. F. Kubicek, D. J. Stuart, and T. J. Gilbertson, “Liquid chromatographic determination of desfuroylceftiofur metabolite of ceftiofur as residue in cattle plasma,” Journal of the Association of Official Analytical Chemists, vol. 73, no. 1, pp. 26–30, 1990. View at Google Scholar · View at Scopus
  13. M. G. Beconi-Barker, R. D. Roof, L. Millerioux et al., “Determination of ceftiofur and its desfuroylceftioufur-related metabolites in swine tissues by high-performance liquid chromatography,” Journal of Chromatography B: Biomedical Applications, vol. 673, no. 2, pp. 231–244, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. W. F. Marshall and J. E. Blair, “The cephalosporins,” Mayo Clinic Proceedings, vol. 74, no. 2, pp. 187–195, 1999. View at Google Scholar · View at Scopus
  15. W. Dürckheimer, F. Adam, G. Fischer, and R. Kirrstetter, “Recent developments in the field of cephem antibiotics,” Advances in Drug Research, vol. 17, pp. 61–234, 1988. View at Publisher · View at Google Scholar
  16. H. C. Neu, “Clinical uses of cephalosporins,” The Lancet, vol. 2, no. 8292, pp. 252–255, 1982. View at Google Scholar · View at Scopus
  17. T. Kuriyama, T. Karasawa, K. Nakagawa, S. Nakamura, and E. Yamamoto, “Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 β-lactam antibiotics,” Oral Microbiology and Immunology, vol. 17, no. 5, pp. 285–289, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. M. W. Climo, S. M. Markowitz, D. S. Williams, C. G. Hale-Cooper, and G. L. Archer, “Comparison of the in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species,” Journal of Antimicrobial Chemotherapy, vol. 40, no. 1, pp. 59–66, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. H. C. Neu, N. X. Chin, and H. B. Huang, “In vitro activity and β-lactamase stability of FK-037, a parenteral cephalosporin,” Antimicrobial Agents and Chemotherapy, vol. 37, no. 3, pp. 566–573, 1993. View at Google Scholar · View at Scopus
  20. H. S. Sader and R. N. Jones, “The fourth-generation cephalosporins: antimicrobial activity and spectrum definitions using cefpirome as an example,” Antimicrobic Newsletter, vol. 9, no. 2, pp. 9–16, 1993. View at Google Scholar
  21. J. Garau, W. Wilson, M. Wood, and J. Carlet, “Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility,” Clinical Microbiology and Infection, vol. 3, no. 1, pp. S87–S101, 1997. View at Google Scholar · View at Scopus
  22. Q. Yang, H. Wang, M. Chen et al., “Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002–2009 Study for Monitoring Antimicrobial Resistance Trends (SMART),” International Journal of Antimicrobial Agents, vol. 36, no. 6, pp. 507–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Barber, U. Giesecke, A. Reichert, and W. Minas, “Industrial enzymatic production of cephalosporin-based beta-lactams,” Advances in Biochemical Engineering/Biotechnology, vol. 88, pp. 179–215, 2004. View at Google Scholar · View at Scopus
  24. A. G. Kambaroudis, S. Papadopoulos, M. Christodoulidou, and T. Gerasimidis, “Perioperative use of antibiotics in intra-abdominal surgical infections,” Surgical Infections, vol. 11, no. 6, pp. 535–544, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Bonfiglio and F. Marchetti, “In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams,” Chemotherapy, vol. 46, no. 4, pp. 229–234, 2000. View at Google Scholar · View at Scopus
  26. J. Garau, “The clinical potential of fourth-generation cephalosporins,” Diagnostic Microbiology and Infectious Disease, vol. 31, no. 3, pp. 479–480, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. W. R. Wilson, “The role of fourth-generation cephalosporins in the treatment of serious infectious diseases in hospitalized patients,” Diagnostic Microbiology and Infectious Disease, vol. 31, no. 3, pp. 473–477, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. Ł. Hońdo, Od odkrycia antybiotyków do Europejskiego Dnia Wiedzy o Antybiotykach, Aptekarz Polski, 2009.
  29. G. Patel and S. Rajput, “Stress degradation studies on cefpodoxime proxetil and development of a validated stability-indicating HPLC method,” Acta Chromatographica, vol. 23, no. 2, pp. 215–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Ikeda, J. Ban, T. Ishikawa, S. Hashiguchi, S. Urayama, and H. Horibe, “Stability and stabilization studies of TAK-599 (ceftaroline fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825,” Chemical and Pharmaceutical Bulletin, vol. 56, no. 10, pp. 1406–1411, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Sugioka, T. Asano, Y. Chikaraishi et al., “Stability and degradation pattern of cefpirome (HR 810) in aqueous solution,” Chemical and Pharmaceutical Bulletin, vol. 38, no. 7, pp. 1998–2002, 1990. View at Google Scholar · View at Scopus
  32. J. O. Fubara and R. E. Notari, “A kinetic oxymoron: concentration-dependent first-order rate constants for hydrolysis of ceftazidime,” Journal of Pharmaceutical Sciences, vol. 87, no. 1, pp. 53–58, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Medenecka, A. Jelińska, M. Zaj̧c, M. Bałdyka, K. Juszkiewicz, and I. Oszczapowicz, “Stability of the crystalline form of cefaclor monohydrate and its pharmaceutical preparations,” Acta Poloniae Pharmaceutica: Drug Research, vol. 66, no. 5, pp. 563–569, 2009. View at Google Scholar · View at Scopus
  34. A. Jelińska, B. Medenecka, M. Zaj̧c, and M. Knajsiak, “The stability of cefprozil in oral suspension CEFZIL,” Acta Poloniae Pharmaceutica: Drug Research, vol. 65, no. 2, pp. 261–265, 2008. View at Google Scholar · View at Scopus
  35. M. Zajac, A. Jeliñska, and P. Zalewski, “Stability of ceftriaxone disodium in biotrakson and tartriakson,” Acta Poloniae Pharmaceutica: Drug Research, vol. 62, no. 2, pp. 89–94, 2005. View at Google Scholar · View at Scopus
  36. A. Jelińska, I. Dudzińska, M. Zając, I. Oszczapowicz, and W. Krzewski, “The stability of Cefuroxime axetil in tablets,” Acta Poloniae Pharmaceutica, vol. 62, pp. 183–187, 2005. View at Google Scholar
  37. P. Zalewski, J. Cielecka-Piontek, P. Garbacki, A. Jelińska, and M. Karaåniewicz-ŁAda, “Stability-indicating HPLC method for the determination of Cefcapene pivoxil,” Chromatographia, vol. 76, no. 7-8, pp. 387–391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. M. J. E. Souza, D. R. Nogueira, L. M. Silva, M. Z. Arend, P. S. Souza Filho, and A. M. Bergold, “Development and validation of an HPLC method for determination of ceftiofur sodium,” Chromatographia, vol. 65, no. 7-8, pp. 401–406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Garbacki, A. Dołhań, and A. Jelińska, Opracowanie metody HPLC do badania trwałości ceftiofuru sodowego, XXII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego, Białystok, Poland, 2013.
  40. A. Dołhań, A. Jelińska, and M. Manuszewska, “Manuszewska, Stability-indicating HPLC method for the determination of cefquinome sulphate,” Acta Poloniae Pharmaceutica, vol. 71, no. 2, pp. 249–264, 2014. View at Google Scholar